Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.
Dingwei Ye, MD, PhD
Advertisement
Articles by Dingwei Ye, MD, PhD
Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5